Multiple roles of ALK3 in osteoarthritis

Abstract

Osteoarthritis (OA) is a chronic degenerative joint disease characterized by progressive cartilage degradation, synovial membrane inflammation, osteophyte formation, and subchondral bone sclerosis. Pathological changes in cartilage and subchondral bone are the main processes in OA. In recent decades, many studies have demonstrated that activin-like kinase 3 (ALK3), a bone morphogenetic protein receptor, is essential for cartilage formation, osteogenesis, and postnatal skeletal development. Although the role of bone morphogenetic protein (BMP) signalling in articular cartilage and bone has been extensively studied, many new discoveries have been made in recent years around ALK3 targets in articular cartilage, subchondral bone, and the interaction between the two, broadening the original knowledge of the relationship between ALK3 and OA. In this review, we focus on the roles of ALK3 in OA, including cartilage and subchondral bone and related cells. It may be helpful to seek more efficient drugs or treatments for OA based on ALK3 signalling in future.

The emerging role of lncRNAs in osteoarthritis development and potential therapy

“…Genetic changes and epigenetics could involve in osteoarthritis development and progression ( Hodgkinson et al, 2022 ; Nunez-Carro et al, 2023 ; Tonutti et al, 2023 ). For example, cellular signaling pathways have been reported to regulate osteoarthritis progression ( Zhang et al, 2023a ; Ruan et al, 2023 ; Zheng et al, 2023 ). In recent years, noncoding RNAs (ncRNAs) have been revealed to participate in osteoarthritis development and progression ( Xie et al, 2020 ).…”